rabi
viru
rabv
infect
continu
global
threat
human
anim
health
yet
cur
therapi
develop
rna
interfer
rnai
therapi
silenc
express
specif
target
gene
repres
promis
approach
treat
viral
infect
mammalian
host
design
six
small
interf
si
rna
target
conserv
region
rabv
challeng
viru
standard
cv
strain
nucleoprotein
n
gene
use
plasmidbas
transient
express
model
demonstr
capabl
significantli
inhibit
viral
replic
vitro
vivo
three
sirna
effect
suppress
rabv
express
infect
babi
hamster
cell
evidenc
direct
immunofluoresc
assay
viral
titer
measur
realtim
pcr
western
blot
addit
liposomemedi
sirna
express
plasmid
deliveri
rabvinfect
mice
significantli
increas
surviv
compar
nonliposomemedi
deliveri
method
collect
result
show
three
sirna
target
n
gene
could
potent
inhibit
rabv
reproduct
sirna
potenti
develop
new
effect
prophylact
antirabv
drug
infect
rabi
viru
rabv
manifest
neurodegen
diseas
known
rabi
fatal
clinic
stage
affect
anim
human
rabi
case
report
worldwid
preval
undevelop
countri
specif
rural
area
africa
asia
definit
treatment
exist
cure
diseas
clinic
stage
reach
small
portion
clinic
case
respond
intens
therapeut
manag
surviv
willoughbi
et
al
thu
current
strategi
control
rabi
preexposur
prophylaxi
vaccin
inject
research
effort
focus
develop
effect
antivir
strategi
establish
rabv
infect
rna
interfer
rnai
consid
one
promis
method
achiev
antivir
defens
rabv
rnai
therapeut
approach
base
abil
doublestrand
small
interf
si
rna
specif
trigger
mrna
degrad
without
caus
signific
cytotox
sirnamedi
gene
silenc
occur
activ
rnainduc
silenc
complex
risc
ubiquit
cytoplasm
protein
complex
harbor
dsrnabind
domain
exonucleas
domain
rnai
approach
alreadi
success
appli
sever
human
pathogen
virus
includ
hepat
b
viru
hbv
morrissey
et
al
song
et
al
dengu
viru
dnv
padwad
et
al
human
immunodefici
viru
hiv
boden
et
al
kumar
et
al
polioviru
saleh
et
al
hepat
c
viru
lupberg
et
al
human
papilloma
viru
niu
et
al
respiratori
syncyti
viru
rsv
bitko
et
al
sever
acut
respiratori
syndrom
sar
coronaviru
li
et
al
influenza
viru
zhang
et
al
addit
sever
research
investig
potenti
rnai
treat
rabv
infect
brandao
et
al
demonstr
sirna
design
rabi
viru
nucleoprotein
n
mrna
abl
partial
protect
cultur
cell
babi
hamster
kidney
bhk
rabi
viru
infect
evidenc
direct
fluoresc
antibodi
test
brandao
et
al
howev
vitro
assay
vivo
data
provid
support
sirna
inhibitori
effect
recent
gupta
et
al
sonwan
et
al
report
adenovir
vectormedi
deliveri
small
hairpin
sh
rna
target
rabv
n
polymeras
l
mrna
led
slight
increas
surviv
rabvinfect
mice
gupta
et
al
sonwan
et
al
viral
vector
undoubtedli
effici
tool
gene
deliveri
use
restrict
sever
inher
featur
pose
potenti
signific
safeti
risk
recipi
exampl
viral
vector
randomli
integr
vector
dna
host
chromosom
addit
vector
may
immunogen
cytotox
specif
tissu
tropism
also
possibl
vector
viru
recombin
wildtyp
virus
gener
potenti
virul
toxic
pathogen
thu
research
gene
therapi
turn
nonvir
gene
deliveri
system
hope
creat
safe
effect
deliveri
system
date
cation
lipid
proven
one
effici
nonvir
gene
transfer
method
amphiphil
molecul
possess
two
element
crucial
gene
deliveri
cation
head
group
condens
dna
lipid
moieti
act
fusogen
group
enhanc
penetr
cell
present
studi
aim
develop
univers
sirna
agent
capabl
target
differ
rabv
strain
n
gene
chosen
studi
sinc
highli
conserv
among
five
rabv
gene
design
six
sirna
specif
conserv
region
rabv
nucleoprotein
gene
sirna
express
vectorbas
transient
express
model
use
determin
abil
inhibit
rabv
replic
vitro
vivo
cell
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
carlsbad
ca
usa
supplement
fetal
bovin
serum
fb
uml
penicillin
gml
streptomycin
hyclon
logan
ut
usa
c
atmospher
co
rabv
challeng
viru
standard
cv
strain
obtain
changchun
institut
veterinari
scienc
china
rabv
use
multipl
infect
moi
vitro
infect
experi
lethal
dose
ld
vivo
mice
challeng
experi
seventytwo
pathogenfre
femal
balbc
mice
weigh
g
changchun
institut
biolog
product
china
use
assess
antivir
activ
six
sirna
vivo
experi
rabv
viru
conduct
biosafeti
level
three
laboratori
facil
changchun
institut
veterinari
scienc
sirna
target
conserv
sequenc
rabv
n
gene
design
dharmacon
sirna
design
algorithm
http
wwwdharmaconcomdesigncenterdesigncenterpageaspx
scrambl
sirna
sequenc
design
use
neg
control
sirna
target
sequenc
includ
control
verifi
specif
rabv
absent
either
human
mu
musculu
genom
perform
blast
search
complementari
singlestrand
dna
oligo
encod
specif
smallhairpin
sirna
shrna
synthes
anneal
clone
hygro
sirna
express
vector
ambion
austin
tx
usa
gener
six
psshrna
plasmid
oligonucleotid
conserv
sequenc
region
encod
specif
shrna
shown
fig
cell
plate
cellswel
plate
incub
overnight
variou
psshrna
plasmid
mix
respect
lipofectamin
transfect
reagent
ratio
use
g
plasmid
l
lipofectamin
invitrogen
carlsbad
ca
usa
optimem
medium
invitrogen
ad
well
scrambl
sirna
plasmid
use
neg
control
h
transfect
transfect
cell
infect
moi
rabv
viru
h
nontransfect
infect
cell
serv
viral
control
transfect
h
infect
supernat
remov
cell
cell
fix
cold
aceton
h
wash
three
time
phosphat
buffer
salin
pb
fluorescein
isothiocyan
fitc
conjug
mous
antin
monoclon
antibodi
prepar
changchun
institut
veterinari
scienc
ad
well
concentr
incub
c
h
immunoreact
observ
fluoresc
microscopi
olympu
japan
viral
titer
measur
use
tissu
cultur
infect
dose
tcid
assay
serial
dilut
supernat
treat
viral
sampl
ad
onto
monolay
cell
cultur
plate
incub
two
day
viru
concentr
measur
dfa
describ
viral
titer
sampl
calcul
reedmuench
method
pandiri
et
al
sirnatransfect
cell
harvest
h
rabv
infect
total
rna
extract
use
trizol
reagent
invitrogen
accord
manufactur
instruct
rna
revers
transcrib
cdna
use
amv
revers
transcriptas
promega
madison
wi
usa
polyt
oligonucleotid
primer
promega
level
n
mrna
transcript
determin
qpcr
use
brilliant
ii
sybr
green
qpcr
master
mix
stratagen
la
jolla
ca
usa
follow
genespecif
primer
forward
revers
bp
amplicon
forward
revers
bp
amplicon
pcr
reaction
l
triplic
carri
mx
system
stratagen
follow
thermal
cycl
condit
c
min
follow
cycl
c
c
min
normal
rel
level
n
mrna
transcript
calcul
doubl
standard
curv
method
use
mxpro
qpcr
softwar
sirnatransfect
cell
harvest
h
rabv
infect
total
protein
sampl
obtain
incub
cell
lysi
buffer
beyotim
biotech
inc
nantong
china
protein
concentr
measur
bicinchonin
acid
bca
protein
assay
pierc
rockford
il
usa
fifti
microgram
aliquot
total
protein
resolv
sodium
sdspage
transfer
nitrocellulos
membran
amersham
bioscienc
uppsala
sweden
result
blot
probe
mous
monoclon
antibodi
rabv
n
protein
mous
monoclon
antibodi
santa
cruz
biotechnolog
santa
cruz
ca
usa
follow
horseradish
peroxidaseconjug
goat
antimous
igg
santa
cruz
biotechnolog
santa
cruz
ca
usa
immunoreact
band
detect
enhanc
chemiluminesc
reagent
pierc
band
area
quantifi
use
imag
j
softwar
us
nation
institut
health
mice
group
nine
inocul
intracerebr
liposomepsshrna
l
dmem
contain
g
psshrna
l
liposom
psshrna
alon
g
h
mice
infect
ld
rabv
intracerebr
site
inocul
mice
observ
day
postinfect
develop
rabiesspecif
symptom
death
intergroup
differ
quantit
data
analyz
ttest
oneway
anova
intergroup
comparison
surviv
rate
carri
logrank
test
statist
analys
perform
spss
ver
statist
softwar
spss
inc
chicago
il
usa
probabl
pvalu
less
consid
statist
signific
evalu
antivir
effect
sirna
target
conserv
sequenc
gene
six
sirna
express
plasmid
neg
control
respect
transfect
cell
dfa
result
indic
construct
mediat
signific
reduct
rabv
n
protein
fluoresc
signal
contrast
three
n
gene
target
sirna
neg
control
effect
fluoresc
signal
compar
nontransfect
viralinfect
control
cell
fig
addit
three
effect
construct
significantli
lower
viral
titer
rel
mrna
level
infect
cell
specif
transfect
rabvinfect
cell
tcid
ml
respect
vs
neg
control
p
fig
viral
rel
mrna
level
group
respect
vs
neg
control
p
fig
determin
durat
sirnamedi
antivir
activ
sirna
robust
inhibit
properti
select
analysi
transfect
infect
cell
supernat
harvest
viral
titer
assay
h
time
point
result
show
signific
inhibit
effect
last
h
h
viral
titer
drop
amount
neg
control
fig
n
protein
express
analyz
transfect
infect
cell
western
blot
vector
led
significantli
reduc
express
compar
neg
control
cell
p
fig
collect
result
demonstr
three
sirna
could
significantli
inhibit
replic
viru
cell
howev
three
sirna
signific
inhibit
properti
exclud
analysi
test
whether
inhibit
rabv
replic
observ
vitro
vector
determin
assay
data
express
mean
log
sd
group
three
separ
experi
p
vs
neg
control
oneway
anova
test
b
qpcr
detect
mrna
transcript
rel
transcript
data
shown
mean
sd
three
separ
experi
p
vs
neg
control
oneway
anova
test
c
time
durat
inhibit
effect
data
express
mean
log
sd
group
three
separ
experi
p
p
vs
neg
control
oneway
anova
test
fig
sirna
target
rabv
n
gene
suppress
n
protein
express
rabv
cell
detect
western
blot
immunoreact
n
protein
band
quantifi
use
imag
j
softwar
express
mean
sd
rel
correspond
protein
p
vs
neg
control
adequ
protect
vivo
use
establish
balbc
mous
model
rabi
viru
mice
first
treat
use
liposomemedi
deliveri
direct
deliveri
liposom
challeng
lethal
dose
ld
rabv
h
later
compar
untreat
sirna
rabvinfect
control
mice
sirnatr
mice
show
fewer
clinic
sign
diseas
lower
morbid
howev
mice
sirnaliposometr
group
show
differ
surviv
rate
mice
treat
sirna
alon
vs
vs
vs
fig
mice
surviv
develop
symptom
rabi
remain
healthi
end
experi
day
fig
liposomemedi
deliveri
sirna
increas
surviv
rabv
mice
mice
treat
intracerebr
psshrna
liposom
psshrna
b
intracerebr
challeng
lethal
h
later
site
challeng
mice
observ
day
percent
surviv
calcul
surviv
group
mice
treat
psshrna
differ
treat
psneg
control
b
surviv
liposom
liposom
group
significantli
differ
liposom
psneg
group
p
p
vs
neg
control
logrank
postchalleng
untreat
control
mice
die
rabv
infect
result
suggest
three
sirna
target
conserv
region
rabv
n
gene
abl
allevi
rabvrel
morbid
could
partial
protect
mice
challeng
lethal
dose
rabi
viru
rna
interfer
emerg
use
techniqu
develop
nucleic
acidbas
gene
silenc
therapeut
treatment
viral
diseas
anesti
et
al
habayeb
et
al
kim
et
al
liu
et
al
pacca
et
al
rnai
achiev
either
endogen
encod
small
rna
known
microrna
mirna
exogen
introduc
synthet
sirna
plasmidvir
vector
construct
contain
shrna
result
collect
vivo
studi
mccaffrey
et
al
phase
clinic
trial
devincenzo
et
al
provid
proofofconcept
rnai
effect
therapeut
agent
human
howev
safeti
concern
remain
sinc
effect
treatment
clinic
rabi
yet
develop
hemachudha
et
al
rnai
consid
promis
therapeut
strategi
rabv
genom
consist
singl
negativestrand
rna
molecul
kb
encod
five
viral
protein
order
rna
transcript
rabv
replic
requir
intric
interplay
nucleoprotein
n
rnadepend
rna
polymeras
rdrp
l
nonenzymat
polymeras
cofactor
p
rna
genom
enwrap
n
also
known
rabv
nucleocapsid
nrna
nrna
complex
act
templat
viral
polymeras
mrna
synthesi
p
l
complex
bind
nrna
templat
np
interact
involv
two
adjac
n
protein
nucleocapsid
lp
bind
nrna
believ
trigger
conform
chang
allow
polymeras
access
rna
albertini
et
al
albertini
et
al
n
p
l
protein
thu
import
factor
viral
transcript
replic
therefor
consid
promis
candid
sirnamirna
inhibit
strategi
fact
studi
sought
identifi
genet
suppressor
element
inhibit
rabv
replic
identifi
n
p
protein
effect
target
israsena
et
al
wunner
et
al
current
studi
attempt
develop
univers
sirna
agent
would
recogn
differ
rabv
strain
use
n
gene
highli
conserv
gene
among
five
rabv
gene
differ
rabv
strain
moreov
select
conserv
sequenc
n
transcript
use
rnai
target
six
sirna
design
three
capabl
significantli
inhibit
rabi
viru
replic
furthermor
vitro
analysi
indic
antivir
activ
last
four
day
vivo
three
could
partial
protect
mice
lethal
dose
rabi
viru
interestingli
deliv
lower
concentr
togeth
liposom
reagent
surviv
rate
significantli
increas
remark
high
extent
result
indic
cellular
uptak
sirna
therapi
depend
dosag
alon
significantli
influenc
carrier
discrep
anim
experi
note
work
best
nake
rna
wors
deliv
liposom
protect
rate
increas
deliv
liposom
consist
theoret
design
howev
result
opposit
work
better
nake
rna
liposom
remain
perplex
find
specul
reason
may
due
distinct
featur
vitro
vivo
environ
moreov
mous
group
random
result
may
reflect
individu
physic
differ
test
mice
nonetheless
mechan
remain
unclear
intend
investig
detail
subsequ
studi
purpos
vivo
experi
verifi
whether
sirna
select
vitro
analysi
effect
vivo
result
show
partial
protect
effect
howev
achiev
complet
protect
sirna
deliveri
method
target
deliveri
rout
intraven
cross
bloodbrain
barrier
dose
singl
multipl
sirna
time
therapeut
administr
assess
gener
optim
treatment
strategi
sinc
sirna
rabv
n
gene
sequenc
capabl
reduc
rabv
replic
protect
mice
rabi
strategi
may
repres
foundat
abovelist
paramet
may
optim
although
difficult
reach
absolut
protect
fact
current
effect
way
cure
rabi
make
agent
promis
candid
adjuv
therapi
exampl
rabv
exposur
vaccin
bodi
gener
need
least
seven
day
produc
antibodi
sirna
adjuv
may
exert
suppress
effect
viru
earli
stage
exposur
conclus
develop
three
sirna
success
target
n
gene
rabv
three
effect
inhibit
rabv
replic
protect
mice
challeng
strain
believ
sirna
potenti
develop
new
effect
prophylact
antirabv
drug
